Sign inCreate account

Report workspace

Add to folder
NCT02576301UNKNOWNanonymous

Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS

Sponsor

Source record

Mateon Therapeutics

Phase

Source record

Phase 1b/2

Modality

AI-normalized

small molecule

Target

AI-normalized

OXi4503 (combretastatin A1-diphosphate) is a vascular-targeted therapy that disrupts tumor vasculature, potentially enhancing the efficacy of cytarabine in treating relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Indication / condition

AI-normalized

Acute Myelogenous Leukemia

Intervention

Source record

Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine

Related intelligence directories

Indication directory: Acute Myelogenous LeukemiaModality directory: small moleculeTarget directory: OXi4503 (combretastatin A1-diphosphate) is a vascular-targeted therapy that disrupts tumor vasculature

Source & freshness

Source record

NCT ID

NCT02576301

Original source

ClinicalTrials.gov

Source last updated

Jun 04, 2018

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02576301

Title

Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS

Sponsor

Mateon Therapeutics

Status

UNKNOWN

Phase

Phase 1b/2

Condition raw

Acute Myelogenous Leukemia, Myelodysplastic Syndromes

Condition normalized

Acute Myelogenous Leukemia, Myelodysplastic Syndromes

Modality raw

small molecule

Modality normalized

small molecule

Target raw

OXi4503 (combretastatin A1-diphosphate) is a vascular-targeted therapy that disrupts tumor vasculature, potentially enhancing the efficacy of cytarabine in treating relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Target normalized

OXi4503 (combretastatin A1-diphosphate) is a vascular-targeted therapy that disrupts tumor vasculature, potentially enhancing the efficacy of cytarabine in treating relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Interventions

Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine

Public preview

Source record

Mateon Therapeutics is advancing OXi4503 through a dual-phase clinical trial aimed at addressing significant unmet needs in relapsed/refractory AML and MDS populations. The combination therapy with cytarabine targets a market with limited effective options post-chemotherapy failure. The successful completion of this trial could position Mateon favorably against competitors in the hematologic oncology space, particularly in the context of increasing demand for innovative therapies in these indications. The trial's outcomes may also attract interest from potential partners or acquirers looking to enhance their oncology portfolios.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT02576301

Status

UNKNOWN

Phase

Phase 1b/2

Sponsor

Mateon Therapeutics

Executive brief

Investment-Ready Snapshot

Mateon Therapeutics is advancing OXi4503 through a dual-phase clinical trial aimed at addressing significant unmet needs in relapsed/refractory AML and MDS populations. The combination therapy with cytarabine targets a market with limited effective options post-chemotherapy failure. The successful completion of this trial could position Mateon favorably against competitors in the hematologic oncology space, particularly in the context of increasing demand for innovative therapies in these indications. The trial's outcomes may also attract interest from potential partners or acquirers looking to enhance their oncology portfolios.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 04, 2018
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02576301

Indication

Acute Myelogenous Leukemia

Modality

small molecule

Target

OXi4503 (combretastatin A1-diphosphate) is a vascular-targeted therapy that disrupts tumor vasculature, potentially enhancing the efficacy of cytarabine in treating relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Intervention

Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.